Association between serum HBV markers and the incidence of developing hepatocellular carcinoma in patients with chronic hepatitis B receiving nucleos(t)ide analogues

Association between serum HBV markers and the incidence of developing hepatocellular carcinoma in patients with chronic hepatitis B receiving nucleos(t)ide analogues - Association between serum HBV markers and the incidence of developing hepatocellular carcinoma in patients with chronic hepatitis B receiving nucleos(t)ide analogues

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012423

Enrollment

1500

Registered

2013-11-27

Start date

2013-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with chronic hepatits B treated with nucleos(t)ide analogues for more than 1 year

Exclusion criteria

Exclusion criteria: under age of 20 coinfection with HCV / HDV / HIV coexistence with other chronic liver disease pregnant or breast-feeding women coexistence with severe disease of other organs, or immunodeficiency patients found to be inadequate by their doctors

Design outcomes

Primary

Measure	Time frame
the cumulative incidence of hepatocellular carcinoma decline of HB surface antigen, loss of HB surface antigen decline of HB core-related antigen suppression of HBV DNA (<2.6LC/mL) ALT normalization HBe antigen seroconversion (applied in patients positive for HBe antigen att baseline)	—

Countries

Japan

Contacts

Public ContactRyoko Yamada

Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology

ryo726@gh.med.osaka-u.ac.jp06-6879-3621

Outcome results